Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects
Despite considerable improvements in the last two decades, chemotherapy-induced nausea and vomiting (CINV) remains a frequent and very bothersome medical problem. It is estimated that about one half to two thirds of all chemotherapy-treated patients experience CINV, the frequency depending on the ch...
Main Authors: | Lorenzo Pradelli, Mario Eandi |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd Medical Publishers
2007-06-01
|
Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/244 |
Similar Items
-
Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
by: Yi Cheng, et al.
Published: (2022-07-01) -
Clinician preference and comparison of the efficacy of ondansetron, granisetron, and palonosetron in preventing chemotherapy-induced nausea and vomiting among children receiving moderate or highly emetogenic chemotherapy
by: Rohan Bansal, et al.
Published: (2023-09-01) -
Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
by: Rashad N, et al.
Published: (2017-03-01) -
Olanzapine enhances the effect of conventional drugs in chemotherapy induced nausea and vomiting: A randomized clinical trial
by: Atefe Khani, et al.
Published: (2022-02-01) -
Comparison of palonosetron and ondansetron to prevent postoperative nausea and vomiting in women using intravenous patient-controlled analgesia
by: Jae Hwa Yoo, et al.
Published: (2020-01-01)